🏭 Glasgow will add a high-speed, isolator-based vial filling line, doubling GMP batch sizes.
📈 Albuquerque’s $200 million expansion also aims to boost clinical and commercial capacity.
🤝 CEO Philip Macnabb highlighted the commitment to support clinical-stage clients with increased manufacturing capabilities.
🔗 Curia continues to strengthen its global network in sterile fill-finish services.
Introduction:
This article discusses the recent expansion plans of Curia Global, Inc., a prominent contract research, development, and manufacturing organization. The focus is on their strategic enhancements to the sterile fill-finish facilities in Glasgow, UK, and Albuquerque, NM, aimed at increasing capacity and improving service delivery to biopharmaceutical clients.
- Curia is expanding its Glasgow facility by adding an integrated vial filling line and lyophilizer, which will enhance production capabilities for various drug products, particularly highly potent compounds.
- The Glasgow expansion will significantly increase the Good Manufacturing Practice (GMP) batch size and improve filling speed and efficiency through the incorporation of robotic technology.
- In Albuquerque, Curia is investing $200 million to augment manufacturing space and capacity, further establishing a robust infrastructure for clinical and commercial drug production.
- The investments respond to rising demands for biologics and other pharmaceutical products while positioning Curia as a key partner in addressing supply chain complexities faced by clients.
- Curia’s enhanced network includes facilities across multiple U.S. locations, providing comprehensive sterile fill-finish services from clinical development to commercial manufacturing.
Conclusion:
With these strategic expansions, Curia Global, Inc. demonstrates its commitment to meeting the increasing demands of the biopharmaceutical industry. This proactive approach not only bolsters Curia’s production capabilities but also positions the company favorably to support clients in navigating the evolving landscape of drug development and commercialization.
